Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 19/20 | 1.00 |
| ▸ | MMP3 | P08254 | 11/20 | 1.00 |
| ▸ | MMP1 | P03956 | 1/20 | 0.62 |
| ▸ | MMP2 | P08253 | 1/20 | 0.62 |
| ▸ | MMP7 | P09237 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6010103 | 0.90 | MMP8 (1.00) | MMP8MMP3MMP1MMP2MMP7 | |
| SCHEMBL29697336 | 0.85 | MMP8 (0.80) | MMP8MMP3MMP1MMP7 | |
| SCHEMBL208179 | 0.85 | MMP8 (0.80) | MMP8MMP3MMP1MMP7 | |
| SCHEMBL30627068 | 0.85 | MMP8 (0.80) | MMP8MMP3MMP1MMP7 | |
| SCHEMBL3495253 | 0.85 | MMP8 (0.80) | MMP8MMP3MMP1MMP7 | |
| SCHEMBL8346417 | 0.79 | MMP8 (0.84) | MMP8MMP3 | |
| SCHEMBL6873972 | 0.79 | MMP8 (0.76) | MMP8MMP3MMP1MMP2MMP7 | |
| SCHEMBL3941015 | 0.78 | MMP8 (0.74) | MMP8MMP3MMP1 | |
| SCHEMBL3941938 | 0.78 | MMP8 (0.74) | MMP8MMP3MMP1 | |
| SCHEMBL6010087 | 0.78 | MMP8 (0.82) | MMP8MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0861236-B2 | CYCLIC AND HETEROCYCLIC N-SUBSTITUTED ALPHA-IMINOHYDROXAMIC AND CARBOXYLIC ACIDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-08-16 | — | — | EP | claimed |
| US-20030176432-A1 | Cyclic and heterocyclic N-substituted alpha-iminohydroxamic and -carboxylic acids | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2003-09-18 | — | — | US | claimed |
| EP-0861236-B1 | CYCLIC AND HETEROCYCLIC N-SUBSTITUTED ALPHA-IMINOHYDROXAMIC AND CARBOXYLIC ACIDS | HOECHST AG (DE) | 2002-02-13 | — | — | EP | claimed |
| US-20010011134-A1 | Cyclic and heterocyclic N-substituted alpha-iminohydroxamic and -carboxylic acids | HOECHST AKTIENGESELLSCHAFT | 2001-08-02 | — | — | US | claimed |
| EP-0861236-A1 | CYCLIC AND HETEROCYCLIC N-SUBSTITUTED ALPHA-IMINOHYDROXAMIC AND CARBOXYLIC ACIDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-09-02 | — | — | EP | claimed |
| WO-1997018194-A1 | CYCLIC AND HETEROCYCLIC N-SUBSTITUTED α-IMINOHYDROXAMIC AND CARBOXYLIC ACIDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-22 | — | — | WO | claimed |
| EP-0861236-B2 | CYCLIC AND HETEROCYCLIC N-SUBSTITUTED ALPHA-IMINOHYDROXAMIC AND CARBOXYLIC ACIDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-08-16 | — | — | EP | disclosed |
| US-6815440-B2 | FOR THERAPY AND PROPHYLAXIS OF DISORDERS IN THE COURSE OF WHICH IS INVOLVED AN INCREASED ACTIVITY OF MATRIX-DEGRADING METALLOPROTEINASES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-09 | — | — | US | disclosed |
| US-20030176432-A1 | Cyclic and heterocyclic N-substituted alpha-iminohydroxamic and -carboxylic acids | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2003-09-18 | — | — | US | disclosed |
| US-6573277-B2 | Metalloproteinase inhibitor | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-06-03 | — | — | US | disclosed |
| EP-0861236-B1 | CYCLIC AND HETEROCYCLIC N-SUBSTITUTED ALPHA-IMINOHYDROXAMIC AND CARBOXYLIC ACIDS | HOECHST AG (DE) | 2002-02-13 | — | — | EP | disclosed |
| US-20010011134-A1 | Cyclic and heterocyclic N-substituted alpha-iminohydroxamic and -carboxylic acids | HOECHST AKTIENGESELLSCHAFT | 2001-08-02 | — | — | US | disclosed |
| US-6207672-B1 | FOR TREATMENT OF CONNECTIVE TISSUE DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011134-A1 | Cyclic and heterocyclic N-substituted alpha-iminohydroxamic and -carboxylic acids | MMP1, MMP2, HPGD | MMP8 5/4885MMP3 15/4885MMP1 1/4885 |
| US-20030176432-A1 | Cyclic and heterocyclic N-substituted alpha-iminohydroxamic and -carboxylic acids | MMP1, MMP2, HPGD | MMP8 5/4885MMP3 15/4885MMP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.